Company Overview - Absci Corporation (NASDAQ:ABSI) was founded in 2018 and is headquartered in Seattle, focusing on integrating deep learning with high-throughput lab automation for biologics design and optimization at scale [2] - The company utilizes its Integrated Drug Creation (IDC) platform, which combines proprietary algorithms with protein engineering to rapidly develop antibody and enzyme candidates for pharmaceutical partners and its own pipeline [2] Recent Developments - Absci recently expanded its partnership with Almirall, launching a second program targeting chronic skin diseases, which builds on the successful delivery of an AI-designed antibody [3] - The company appointed experts Dr. Rodney Sinclair and Dr. David Goldberg to advise on ABS-201, an AI-designed therapy for hair loss disorders, expected to enter clinical evaluation in early 2026 [3] Technological Advancements - Absci announced collaborations with Oracle Cloud Infrastructure and AMD to enhance its AI-driven drug discovery capabilities [4] - The partnership with AMD includes a strategic investment, providing access to advanced chip technology and cloud resources for scaling model training and data processing [4] Financial Position - Absci secured $64 million in equity financing during July and August 2025, extending its operational runway through mid-2028 [5] - The funding will support the advancement of key pipeline programs, including ABS-101 and ABS-201, while accelerating partnered projects and strengthening the corporation's AI infrastructure for next-generation drug discovery [5]